Aequus Pharmaceuticals Inc - Asset Resilience Ratio
Aequus Pharmaceuticals Inc (AQS) has an Asset Resilience Ratio of 4.11% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aequus Pharmaceuticals Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Aequus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Aequus Pharmaceuticals Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Aequus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Aequus Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$44.85K | 4.11% |
| Total Liquid Assets | CA$44.85K | 4.11% |
Asset Resilience Insights
- Limited Liquidity: Aequus Pharmaceuticals Inc maintains only 4.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aequus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Aequus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Aequus Pharmaceuticals Inc (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Aequus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 4.13% | CA$44.85K ≈ $32.44K |
CA$1.09 Million ≈ $785.76K |
+1.48pp |
| 2022-12-31 | 2.65% | CA$44.85K ≈ $32.44K |
CA$1.69 Million ≈ $1.22 Million |
+1.62pp |
| 2021-12-31 | 1.03% | CA$44.89K ≈ $32.47K |
CA$4.35 Million ≈ $3.15 Million |
+1.03pp |
| 2020-12-31 | 0.00% | CA$123.00 ≈ $88.98 |
CA$3.13 Million ≈ $2.27 Million |
-31.81pp |
| 2017-12-31 | 31.81% | CA$850.00K ≈ $614.88K |
CA$2.67 Million ≈ $1.93 Million |
-- |
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more